We found CXCR3 positivity in 5–35% of tumor area in 17 out of 30 patients, whilst 9 out of 30 patients had less than 5% CXCR3 positivity in tumor tissue and 4 patients showed no CXCR3 expression (Figure 4C). This evidence concerns the gene CXCR3 and neoplasm.